Caroline Dive (born April 1962) is a British cancer research scientist. Dive is Professor of Cancer Pharmacology at the University of Manchester, Deputy Director of the Cancer Research UK (CRUK) Manchester Institute, Director of the CRUK Manchester Institute Cancer Biomarker Centre and co-director of the CRUK Lung Cancer Centre of Excellence. She is the current President of The European Association for Cancer Research (EACR). Dive's citation upon election as Fellow of the Academy of Medical Sciences describes her as internationally renowned for her work on the development of liquid biopsy methods which use biomarkers circulating in the blood, such as circulating tumour cells and cell-free tumour DNA, to diagnose and monitor cancer. Education Dive was educated at the University of London, where she awarded a First Class Honours Bachelor of Pharmacy in 1984. She went on to complete her postgraduate degree in Experimental Cancer Chemotherapy at the MRC Clinical Oncology and Radiotherapeutic Unit in Cambridge. Research After completing her PhD, Caroline set up her own group at Aston University's School of Pharmaceutical Sciences in Birmingham, studying the mechanisms of drug induced tumour cell death. She then moved to what became the Faculty of Life Sciences at the University of Manchester and was awarded a Lister Institute of Preventative Medicine Research Fellowship before moving to the Cancer Research UK Manchester Institute in 2003. It was at the Manchester Institute that she moved away from basic cancer research to set up a new translational research team focussed on biomarkers, working closely with The Christie Hospital in Manchester. She set up the Clinical Pharmacology Fellowship scheme in 2005 and has been training clinical fellows in the lab ever since. Dive and her team are developing ‘liquid biopsies’ to hunt cancer cells that have broken free from tumours and are circulating in the bloodstream. Her focus is lung cancer. Dive says the most important work she's published so far was in 2014, which she said was "a real step change for small cell lung cancer research." They showed that it's possible to take tumour cells that are circulating in a patient's blood and grow them to form tumours in the lab in mice. It was the first time a small cell lung tumour has been grown in this way and didn't require an invasive biopsy. This work allows the team to study lung cancer biology and test new treatments. The work was published in